Enabling speed to clinic for monoclonal antibody programs using a pool of clones for IND-enabling toxicity studies

• Asıl Yazarlar: Parimala Bolisetty (Yazar), Gabi Tremml (Yazar), Sen Xu (Yazar), Anurag Khetan (Yazar)
• Materyal Türü: Kitap
• Baskı/Yayın Bilgisi: Taylor & Francis Group, 2020-01-01T00:00:00Z.
• Konular: article
• Online Erişim: Connect to this object online.

The importance of speed to clinic for medicines that may address unmet medical needs puts pressure on product development timelines. Historically, both toxicology and first-in-human clinical materials are generated using the same clonal-derived cells to ensure safety and minimize any development ris...